natgillin/translations-raw huggingface dataset:
• Common side effects (may affect up to 1 in 10 people): - stomach pain - chest pain - headache - anxiety - injection site pain - vomiting
• Česte nuspojave (mogu se javiti u najviše 1 na 10 osoba): - bol u trbuhu - bol u prsištu - glavobolja - tjeskoba - bol na mjestu injiciranja - povraćanje
There are no adequate data from the use of methylthioninium chloride in pregnant women.
Nema odgovarajućih podataka o primjeni metiltioninijeva klorida u trudnica.
Acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Akutno simptomatsko liječenje methemoglobinemije uzrokovane lijekovima i kemikalijama.
These include SSRIs (selective serotonin reuptake inhibitors), bupropion, buspirone, clomipramine, mirtazapine, and venlafaxine.
Ti lijekovi uključuju SSRI-e (selektivni inhibitori ponovne pohrane serotonina), bupropion, buspiron, klomipramin, mirtazapin i venlafaksin.
• Selective serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, fluoxetine,
• selektivne inhibitore ponovne pohrane serotonina (SSRI) kao što su citalopram, escitalopram,
The use of Methylthioninium chloride Proveblue during pregnancy is not recommended unless it is clearly necessary, for example in a life-threatening situation.
Ne preporučuje se koristiti Methylthioninium chloride Proveblue tijekom trudnoće, osim ako je to neophodno potrebno, na primjer u situaciji opasnoj po život.
If any of the above applies to you, please consult your doctor.
Ako se bilo što od gore navedenog odnosi na Vas, obratite se svom liječniku.
Methylthioninium chloride Proveblue must be injected very slowly over a period of 5 minutes to prevent high local concentrations of the compound from producing additional methaemoglobin.
Methylthioninium chloride Proveblue mora se injicirati vrlo sporo tijekom perioda od 5 minuta da bi se spriječilo da visoke lokalne koncentracije lijeka prouzrokuju stvaranje dodatnog methemoglobina.
• mirtazapine
• mirtazapin
• Monoamine oxidase inhibitors
• inhibitore monoaminooksidaze
In the case of aniline- or dapsone-induced methaemaglobinaemia, the maximum recommended cumulative dose for the course of treatment is 4 mg/kg (see section 4.4).
U slučaju methemoglobinemije uzrokovane anilinom ili dapsonom, maksimalna preporučena kumulativna doza tijekom cjelokupnog liječenja je 4 mg/kg (vidjeti dio 4.4).
Marketing Authorisation Holder Provepharm SAS
Nositelj odobrenja za stavljanje lijeka u promet Provepharm SAS
In vivo, in low concentration, methylthioninium chloride speeds up the conversion of methaemoglobin to haemoglobin.
In vivo, u niskoj koncentraciji, metiltioninijev klorid ubrzava pretvorbu methemoglobina u hemoglobin.
Avoid concomitant use of methylthioninium chloride with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (see section 4.5).
Izbjegavajte istodobnu uporabu metiltioninijevog klorida sa selektivnim inhibitorima ponovne pohrane serotonina (SSRI), inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI) te inhibitorima monoaminooksidaze (vidjeti dio 4.5).
Due to a lack of available data on whether methylthioninium chloride passes into human breast milk, breast-feeding should be discontinued for up to 8 days after treatment with this medicine.
Zbog nepostojanja dostupnih podataka izlučuje li se metiltioninijev klorid u majčino mlijeko u ljudi, dojenje treba prekinuti do 8 dana nakon prestanka liječenja ovim lijekom.
For storage conditions of the diluted medicinal product, see section 6.3.
Za uvjete čuvanja razrijeđenog lijeka, vidjeti dio 6.3.
Solution for injection 5 ampoules of 10 ml
Otopina za injekciju 5 ampula od 10 ml
Some evidence of carcinogenic activity of methylthioniniul chloride has been shown in male mice and male rats.
Pokazani su neki dokazi kancerogene aktivnosti metiltioninijeva klorida u muških miševa i muških štakora.
The maximum recommended cumulative dose for the course of treatment is 7 mg/kg and should not be exceeded, since Methylthioninium chloride administered above the maximum dose may cause methaemoglobinaemia in susceptible patients.
Maksimalna preporučena kumulativna doza tijekom liječenja je 7 mg/kg i ne smije se prekoračiti jer metiltioninijev klorid primijenjen iznad maksimalne doze lijeka kod podložnih bolesnika može uzrokovati methemoglobinemiju.
The most commonly reported adverse reactions observed during clinical trials are dizziness, paraesthesia, dysgeusia, nausea, skin discoloration, chromaturia, sweating, injection site pain and pain in extremity.
Najčešće prijavljene nuspojave zabilježene u kliničkim ispitivanjima su omaglica, parestezije, disgeuzija, mučnina, promjena boje kože, kromaturija, znojenje, bol na mjestu injiciranja i bol u ekstremitetu.
If symptoms of serotonin syndrome occur, discontinue use of methylthioninium chloride, and initiate supportive treatment.
Ako dođe do pojave simptoma serotoninskog sindroma, prekinite uporabu metiltioninijevog klorida i započnite potporno liječenje.
Do not drive or use any tools or machines as methylthioninium chloride has moderate influence on the ability to drive and use machines.
Nemojte upravljati vozilima i strojevima jer metiltioninijev klorid ima umjereni utjecaj na sposobnost upravljanja vozilima i strojevima.
Methylthioninium chloride (also called methylene blue) belongs to a group of medicines called antidotes.
Metiltioninijev klorid (koji se još naziva i metilensko plavilo) pripada grupi lijekova koji se zovu protuotrovi.
Methylthioninium chloride may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs.
Metiltioninijev klorid može izazvati ozbiljan ili fatalan serotoninski sindrom kada se koristi u kombinaciji sa serotonergičkim lijekovima.
Methylthioninium chloride Proveblue will be given to you or your child (0-17 years old) to treat problems with your blood resulting from exposure to some medicines or chemicals that can cause a disease called methaemoglobinaemia.
Vi ili Vaše dijete (0-17 godina starosti) ćete dobiti Methylthioninium chloride Proveblue za liječenje problema s krvi koji proizlaze iz izlaganja nekim lijekovima ili kemikalijama koje mogu uzrokovati bolest koja se zove methemoglobinemija.
- if you suffer from hyperglycaemia or diabetes mellitus, as these conditions may be worsened by the glucose solution used for the dilution of the medicine - your urine and stools may turn a blue-green colour; and skin may possibly turn a blue colour when you are treated with Methylthioninium chloride Proveblue.
- ako bolujete od hiperglikemije ili šećerne bolesti, jer otopina glukoze koja se koristi za razrjeđivanje lijeka može pogoršati ova stanja - Vaša mokraća i stolica mogu postati plavo-zelene boje i koža može poplaviti kada se liječite lijekom Methylthioninium chloride Proveblue.
The clinical consequences of increases plasma concentration of co-administered drugs which are sensitive CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A substrates cannot be ruled out.
Nije moguće isključiti kliničke posljedice povećanja plazmatske koncentracije istodobno primijenjenih lijekova koji su osjetljivi supstrati CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A.
Your skin may turn blue blue or green urine numbness and tingling abnormal taste in mouth nausea
Koža vam može poplaviti - plava ili zelena mokraća - utrnulost i trnci - abnormalan okus u ustima - mučnina
The administration of large intravenous doses (≥ 7 mg/kg) of Methylthioninium chloride Proveblue to individuals without methaemoglobinaemia induces nausea and vomiting, chest tightness, chest pain, tachycardia, apprehension, severe sweating, tremor, mydriasis, blue-green staining of the urine, blue staining of the skin and mucous membranes, abdominal pain, dizziness, paraesthesia, headache, confusion, hypertension, mild methaemoglobinaemia (up to 7%) and electrocardiogram changes (T wave flattening or inversion).
Primjena velikih intravenskih doza (≥ 7 mg/kg) lijeka Methylthioninium chloride Proveblue u osoba bez methemoglobinemije izaziva mučninu i povraćanje, stezanje u prsištu, bol u prsištu, tahikardiju, strah, jako znojenje, tremor, midrijazu, plavo-zelenu obojenost mokraće, plavo obojenje kože i sluznica, bol u abdomenu, omaglicu, paresteziju, glavobolju, konfuziju, hipertenziju, blagu methemoglobinemiju (do 7%) i promjene na elektrokardiogramu (ravnanje ili inverziju T vala).
The excretion of methylthioninium chloride in milk has not been studied in animals.
Izlučivanje metiltioninijeva klorida u mlijeko nije ispitivano na životinjama.
Methylthioninium chloride was mutagenic in gene mutation assays in bacteria and mouse lymphoma cells but not in vivo mouse micronucleus assay when administered intravenously at 62 mg/kg.
Metiltioninijev klorid je bio mutagen u testovima mutacije gena u bakterija i stanicama limfoma miševa, ali ne i na in vivo mikronukleusnom testu miševa kod intravenske primjene 62 mg/kg.
• clomipramine
• klomipramin
52, Rue Marcel et Jacques Gaucher 94120 Fontenay-sous-Bois France
52, Rue Marcel et Jacques Gaucher 94120 Fontenay-sous-Bois Francuska
Too limited data are available to support a continuous infusion dose recommendation.
Za preporuku doze za kontinuiranu infuziju ne postoji dovoljno dostupnih podataka.
It imparts a blue-green colour to urine, faeces and a blue colour to skin which may hinder a diagnosis of cyanosis.
Uzrokuje plavo-zelenu boju mokraće, stolice te plavu boju kože zbog koje može onemogućiti dijagnosticiranje cijanoze.
Based on kinetic data, breast-feeding should be discontinued for up to 8 days after treatment with Methylthioninium chloride Proveblue.
Na temelju kinetičkih podataka, dojenje treba prekinuti do 8 dana nakon prestanka liječenja lijekom Methylthioninium chloride Proveblue.
5 ampoules of 2 ml 20 ampoules of 2 ml 10 mg/2 ml
5 ampula od 2 ml 20 ampula od 2 ml 10 mg/2 ml
Extreme caution should be exercised when administering to newborns and infants below the age of 3 months due to lower concentrations of NADPH-methaemoglobin reductase necessary for reducing methaemoglobin to haemoglobin, making these infants more susceptible to methaemoglobinaemia produced by high doses of methylthioninium chloride.
Nužan je izraziti oprez pri primjeni u novorođenčadi i dojenčadi mlađe od 3 mjeseca zbog nižih koncentracija NADPH-methemoglobin reduktaze potrebne za redukciju methemoglobina u hemoglobin, zbog čega je dojenčad podložnija methemoglobinemiji uzrokovanoj visokim dozama metiltioninijeva klorida.
You should not be given this medicine after the expiry date which is printed on the carton and the ampoule labels after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnicama ampule iza „Rok valjanosti“ ili „EXP“.
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance serotonergic transmission because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.
Metiltioninijev klorid trebaju izbjegavati bolesnici koji primaju lijekove koji pojačavaju serotonergički prijenos zbog potencijalnih ozbiljnih reakcija SŽS-a, uključujući potencijalno fatalni serotoninski sindrom.
Methylthioninium chloride Proveblue can exacerbate dapsone-induced haemolytic anemia because of the formation of the dapsone reactive metabolite hydroxylamine which oxidises haemoglobin.
Methylthioninium chloride Proveblue može pogoršati hemolitičku anemiju izazvanu dapsonom zbog stvaranja reaktivnog metabolita dapsona hidroksilamina, koji oksidira hemoglobin.
Preparation for intravenous administration
Priprema za intravensku primjenu
Patients with hyperglycaemia or diabetes mellitus
Bolesnici s hiperglikemijom ili šećernom bolesti
What Methylthioninium chloride Proveblue is and what it is used for What you need to know before you are given Methylthioninium chloride Proveblue How Methylthioninium chloride Proveblue is given Possible side effects
Što je Methylthioninium chloride Proveblue i za što se koristi Što morate znati prije nego primite Methylthioninium chloride Proveblue Kako primjenjivati Methylthioninium chloride Proveblue Moguće nuspojave
Methylthioninium chloride is an in vitro inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5.
Metiltioninijev klorid je in vitro inhibitor CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A4/5.
How to store Methylthioninium chloride Proveblue Contents of the pack and other information
Kako čuvati Methylthioninium chloride Proveblue Sadržaj pakiranja i druge informacije
It must be injected very slowly over a period of 5 minutes.
Lijek se mora injicirati vrlo sporo tijekom perioda od 5 minuta.
• Patients with methaemoglobinaemia due to chlorate poisoning
• Bolesnici s methemoglobinemijom zbog trovanja kloratom
Methylthioninium chloride is a potent inhibitor of the transporters OCT2, MATE1 and MATE2-K.
Metiltioninijev klorid snažan je inhibitor transportera OCT2, MATE1 i MATE2-K.
The administration of methylthioninium chloride Proveblue has the potential to transiently increase or decrease the clearance of drugs that are primarily metabolized by these enzymes.
Primjena lijeka Methylthioninium chloride Proveblue može prolazno povećati ili smanjiti klirens lijekova koji se prvenstveno metaboliziraju ovim enzimima.
Adverse reactions, seen at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were moderate regenerative anaemia associated with increased mean platelet count and fibrinogen levels, a minimal increase in mean total bilirubin blood values and an increased incidence of moderate urine bilirubin levels.
Nuspojave, viđene na razinama izloženosti sličnim kliničkim razinama izloženosti i uz mogući značaj za kliničku primjenu su bile umjerena regenerativna anemija povezana s povišenjem srednje vrijednosti broja trombocita i razina fibrinogena, malo povišenje srednjih vrijenosti razina bilirubina u krvi i povećanje incidencije umjerenih razina bilirubina u mokraći.
Cenexi 52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, France
Cenexi 52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, Francuska
You must not be given Methylthioninium chloride Proveblue: - if you are allergic to methylthioninium chloride or other thiazine dyes - if your body does not produce enough of the enzyme G6PD (glucose-6-phosphate dehydrogenase) - if your body does not produce enough of the enzyme NADPH (nicotinamide adenine dinucleotide phosphate) reductase - if your blood disorder has been caused by nitrite during treatment of cyanide poisoning - if your blood disorder has been caused by chlorate poisoning.
Ne smijete primiti Methylthioninium chloride Proveblue: - ako ste alergični na metiltioninijev klorid ili druge tiazinske boje - ako Vaše tijelo ne stvara dovoljno enzima G6PD (glukoza-6-fosfat dehidrogenaza) - ako Vaše tijelo ne stvara dovoljno enzima NADPH (nikotinamid adenin dinukleotid fosfat)
Methylthioninium chloride Proveblue is not an in vitro substrate for BCRP or OCT2 and is not an in vitro inhibitor of BCRP, OAT1 or OAT3.
Methylthioninium chloride Proveblue nije in vitro supstrat za BCRP ili OCT2 i nije in vitro inhibitor BCRP, OAT1 ili OAT3.
Individuals without methaemoglobinaemia
Osobe bez methemoglobinemije
What Methylthioninium chloride Proveblue is and what it is used for
Što je Methylthioninium chloride Proveblue i za što se koristi
Caution should be exercised in the course of treatment with methylthioninium chloride as this may exacerbate Heinz body formation and haemolytic anaemia.
Nužan je oprez tijekom liječenja metiltioninijevim kloridom jer može pogoršati formiranje Heinzovih tijela i hemolitičke anemije.
When used in combination with these medicines methylthioninium chloride may cause serotonin syndrome, which can be potentially life-threatening.
Kada se koristi u kombinaciji s tim lijekovima, metiltioninijev klorid može izazvati serotoninski sindrom koji može biti opasan po život.
Type I glass ampoules.
Ampule od stakla tipa I.
In cases of suspected methaemoglobinaemia, it is advisable to check the oxygen saturation by cooximetry when available since pulse oximetry may provide a false estimation of oxygen saturation during administration of methylthioninium chloride.
U slučajevima sumnje na methemoglobinemiju, savjetuje se provjeriti zasićenost kisikom putem kooksimetrije, ako je moguće, jer tijekom primjene metiltioninijeva klorida, pulsna oksimetrija može dati pogrešnu procjenu zasićenosti kisikom.
• Patients with nitrite-induced methaemoglobinaemia during treatment of cyanide poisoning
• Bolesnici s methemoglobinemijom uzrokovanom nitritom tijekom liječenja trovanja cijanidom
What Methylthioninium chloride Proveblue looks like and contents of the pack Methylthioninium chloride Proveblue is a clear dark blue solution for injection (injection) and is supplied in clear glass ampoules.
Kako Methylthioninium chloride Proveblue izgleda i sadržaj pakiranja Methylthioninium chloride Proveblue je bistra tamnoplava otopina za injekciju (injekcija) i isporučuje se u prozirnim staklenim ampulama.
In patients with aniline-induced methaemoglobinaemia, repeated doses of methylthioninium chloride may be required.
U bolesnika s methemoglobinemijom izazvanom anilinom mogu biti potrebne ponovljene doze metiltioninijeva klorida.
• buspirone
• buspiron
Anaesthesiologists should be vigilant for methaemoglobinaemia in patients receiving dapsone therapy and for BIS (Bispectral Index) interference with Methylthioninium chloride Proveblue administration.
Anesteziolozi moraju obratiti posebnu pozornost na methemoglobinemiju u bolesnika koji primaju terapiju dapsona i interferenciju BIS-a (bispektralni indeks) tijekom primjene Methylthioninium chloride Proveblue.
Failure to respond to methylthioninium chloride suggests cytochrome b5 reductase deficiency, glucose6- phosphate dehydrogenase deficiency or sulfhaemoglobinemia.
Nedostatak reakcije na metiltioninijev klorid ukazuje na pomanjkanje citokrom-b5-reduktaze, pomanjkanje glukoza-6-fosfat-dehidrogenaze ili sulfhemoglobinemiju.
Cumulative doses of Methylthioninium chloride may lead to dyspnoea and tachypnoea, presumably related to reduced oxygen availability caused by methaemoglobinaemia, chest pain, tremor, cyanosis and haemolytic anaemia.
Kumulativne doze metiltioninijeva klorida mogu dovesti do dispneje i tahipneje, koje su vjerojatno povezane sa smanjenom dostupnosti kisika uzrokovanom methemoglobinemijom, do boli u prsištu, tremora, cijanoze i hemolitičke anemije.
It is recommended not to exceed a cumulative dose for the course of treatment of 4 mg/kg in patients with dapsone-induced methaemoglobinaemia.
Tijekom liječenja ne preporučuje se prekoračenje kumulativne doze od 4 mg/kg u bolesnika s methemoglobinemijom izazvanom dapsonom.
Haemolytic anaemia
Nepoznato hemolitička anemija
In vitro, methylthioninium chloride has been shown to reduce motility of human sperm in a dose dependant manner.
In vitro, metiltioninijev klorid je pokazao da smanjuje pokretljivost ljudskih spermija ovisno o dozi.
The administration of methylthioninium chloride Proveblue has the potential to transiently increase the exposure of drugs primarily cleared by renal transport involving the OCT2/MATE pathway, including cimetidine, metformin and acyclovir.
Primjena lijeka Methylthioninium chloride Proveblue može prolazno povećati izloženost lijekovima koji se prvenstveno eliminiraju putem bubrega, transportom koji uključuje OCT2/MATE put, uključujući cimetidin, metformin i aciklovir.
Methylthioninium chloride Proveblue should not be used during pregnancy unless clearly necessary, e.g. in life-threatening methaemoglobinaemia.
Methylthioninium chloride Proveblue ne smije se primjenjivati tijekom trudnoće, osim ako je to neophodno, npr. u slučaju methemoglobinemije opasne po život.
It must especially not be mixed with sodium chloride 9 mg/ml (0.9%) solution for injection because it has been demonstrated that chloride reduces the solubility of methylthioninium chloride.
Osobito se ne smije miješati s otopinom natrijevog klorida 9 mg/ml (0,9 %) za injekcije jer je dokazano da kloridi smanjuju topljivost metiltioninijeva klorida.
No evidence of carcinogenic activity was observed in female rats.
Nije opažen dokaz kancerogene aktivnosti u ženki štakora.
Methylthioninium chloride is a substrate of P-glycoprotein (P-gp).
Metiltioninijev klorid supstrat je P-glikoproteina (P-gp).
Methylthioninium chloride may cause a photosensitivity reaction in the skin (sunburn-like reaction) when exposed to strong light sources, such as light therapy, lights in operating rooms and pulse oximeters.
Metiltioninijev klorid može izazvati reakciju fotosenzitivnosti na koži (reakciju sličnu opeklinama od sunca) prilikom izlaganja izvorima snažnog svjetla, kao što je terapija svjetlom, svjetla u operacijskim salama i svjetla pulsnih oksimetara.
If you are given more Methylthioninium chloride Proveblue than you should As this medicine will be given to you whilst you are in hospital, it is unlikely that you will be given too much or too little, however, tell your doctor if you notice one of the following adverse reactions: - feeling sick, - stomach pain, - chest pain, - dizziness, - headache, - sweating, - confusion, - an increase in methaemoglobin (an abnormal form of haemoglobin in the blood), - high blood pressure, - shortness of breath, - abnormally fast beating of the heart, - tremor, - skin discolouration.
S obzirom na to da ćete ovaj lijek primati dok ste u bolnici, malo je vjerojatno da ćete primiti previše ili premalo lijeka, ali ipak, recite liječniku ako primijetite jednu od sljedećih nuspojava: - mučnina, - bol u trbuhu, - bol u prsištu, - omaglicu, - glavobolju, - znojenje, - smetenost, - povišenje methemoglobina (nenormalan oblik hemoglobina u krvi), - povišen krvni tlak, - nedostatak zraka, - nenormalno brzo kucanje srca, - tremor, - promjena boje kože.
Individuals with methaemoglobinaemia
Osobe s methemoglobinemijom
What you need to know before you are given Methylthioninium chloride Proveblue
Što morate znati prije nego primite Methylthioninium chloride Proveblue
Methylthioninium chloride Proveblue is not an in vitro inducer of CYP2B6 and CYP3A4.
Methylthioninium chloride Proveblue nije in vitro induktor CYP2B6 i CYP3A4.
Patients treated with methylthioninium chloride in combination with serotonergic drugs should be monitored for the emergence of serotonin syndrome.
Bolesnike koji se liječe metiltioninijevim kloridom u kombinaciji sa serotonergičkim lijekovima treba pratiti zbog moguće pojave serotoninskog sindroma.
Methylthioninium chloride has moderate influence on the ability to drive and use machines.
Metiltioninijev klorid umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
A repeat dose (0.3 to 0.5 mg/kg body weight, i.e. 0.06-0.1 ml/kg body weight) may be given one hour after the first dose in cases of persistent or recurrent symptoms or if methaemoglobin levels remain significantly higher than the normal clinical range (see section 4.4 for important safety information).
Ponovljenu dozu (0,3 do 0,5 mg/kg tjelesne težine, tj. 0,06 do 0,1 ml/kg tjelesne težine) moguće je primijeniti jedan sat nakon prve doze u slučajevima perzistentnih ili rekurentnih simptoma ili ako su razine methemoglobina ostanu znatno više od normalnog kliničkog raspona (za važne informacije o sigurnosti vidjeti dio 4.4).
It must not be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection because it has been demonstrated that chloride reduces the solubility of methylthioninium chloride.
Ne smije se razrjeđivati s otopinom natrijevog klorida 9 mg/ml (0,9%) za injekcije jer je dokazano da kloridi smanjuju topljivost metiltioninijeva klorida.
A repeat dose (0.3 to 0.5 mg/kg body weight, i.e. 0.06-0.1 ml/kg) may be given after one hour in case of persistence or recurrence of symptoms.
Ponovljenu dozu (0,3 do 0,5 mg/kg tjelesne težine, tj. 0,06-0,1 ml/kg) moguće je dati nakon jedan sat u slučaju neprestajanja ili ponovne pojave simptoma.